Oncolix, Inc. (AEPP) Starts Presentation at LD Micro Main Event
Oncolix (OTC: AEPP) is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers. The company has a US FDA-cleared IND to commence human testing of Prolanta™ in the treatment of ovarian cancer. Prolanta™ is a prolactin receptor antagonist that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. There is also strong preclinical evidence Prolanta™ may be effective in breast, prostate and other cancers. The FDA has approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer. For more information, visit the company’s website…
